Genotype-phenotype correlations of amyotrophic lateral sclerosis

Hong-Fu Li and Zhi-Ying Wu

Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by progressive neuronal loss and degeneration of upper motor neuron (UMN) and lower motor neuron (LMN). The clinical presentations of ALS are heterogeneous and there is no single test or procedure to establish the diagnosis of ALS. Most cases are diagnosed based on symptoms, physical signs, progression, EMG, and tests to exclude the overlapping conditions. Familial ALS represents about 5 ~ 10 % of ALS cases, whereas the vast majority of patients are sporadic. To date, more than 20 causative genes have been identified in hereditary ALS. Detecting the pathogenic mutations or risk variants for each ALS individual is challenging. However, ALS patients carrying some specific mutations or variant may exhibit subtly distinct clinical features. Unraveling the respective genotype-phenotype correlation has important implications for the genetic explanations. In this review, we will delineate the clinical features of ALS, outline the major ALS-related genes, and summarize the possible genotype-phenotype correlations of ALS.

Keywords: Amyotrophic lateral sclerosis, Diagnosis of ALS, Causative genes, Genetic explanations, Genotype-phenotype correlations

Background
Amyotrophic lateral sclerosis (ALS) is a devastating and inexorable neurodegenerative disease characterized by progressive neuronal loss and degeneration of upper motor neuron (UMN) and lower motor neuron (LMN) [1]. It is the most widespread type of motor neuron disease and has become the third most common neurodegenerative disease in the world [2]. Patients affected with ALS typically suffer from progressive muscle weakness and atrophy and usually die from respiratory failure 2 to 3 years after the onset [3]. ALS is a relentless and incurable disease. There has been no effective therapeutic approach to halt the progression so far. ALS is heterogeneous in its presentation, course, and progression. No single test for diagnosing ALS exists; most cases are diagnosed based on symptoms, physical signs, progression, EMG, and tests to exclude the overlapping conditions.

The etiology of ALS is not fully understood. Appropriate 5 ~ 10 % of ALS is familial (FALS) with a Mendelian pattern of inheritance, suggesting that genetic factors play important roles in the pathogenesis of ALS [4]. To date, more than 20 causative genes have been identified in hereditary ALS. In addition, about 30 potential causative or disease-modifying genes have also been identified. Detecting the pathogenic mutations or risk variants for each ALS individual is therefore challenging. Clinical features do not reliably separate the hereditary ALS from sporadic ALS (SALS) due to phenotypic overlap. However, ALS patients carrying some specific mutations may exhibit subtly distinct clinical features. Unraveling the genotype-phenotype correlations has important implications for the genetic explanations. In this review, we will delineate the clinical features of ALS, outline the major ALS-related genes, and review the possible genotype-phenotype correlations. We hope this review will be in favor of improving the accuracy of genetic screenings.

Clinical features of ALS
ALS usually commences in later life, with a mean age at onset (AAO) of 65 year. The onset for FALS tends to be earlier than that of SALS. A small proportion of patients may developed juvenile ALS (JALS), in which onset occurs in the first two decades [5]. Symptoms usually begin
in the limbs (termed limb onset), although approximate 25 % of ALS patients have bulbar onset. Associated with poorer prognosis, bulbar onset is more common in elderly patients and women [6]. Upper limb weakness and atrophy at onset are most common, subsequently spreading to involve bulbar, trunk, or respiratory muscle [7]. After initial presentation of symptoms, the disease progresses to include both UMN and LMN symptoms and signs. The UMN disturbance involving limbs leads to spasticity, weakness, and brisk reflexes. The LMN features of limbs comprise muscle atrophy, weakness, fasciculation, and decreased reflexes. As limb function deteriorates, patients gradually lose their ability to walk. Bulbar UMN dysfunction includes spastic dysarthria and brisk jerk of gag and jaw, while bulbar LMN dysfunction includes tongue wasting, weakness, and fasciculation. In the later stage of ALS, most cases develop dysphagia, which are associated with weight loss and malnutrition.

Sensory loss is usually absent, but cognitive impairment is common in ALS cases. A significant proportion of ALS cases develop cognitive dysfunction, and in a minority, overt dementia [7]. With appropriate cognitive assessment, 20 ~ 50 % of patients with ALS fulfill the consensus criteria for probable or definite frontal temporal dementia (FTD) [8]. In addition, about 30 % of FTD patients manifest signs of motor system dysfunction [9]. The occurrence of ALS, FTD, or ALS with FTD in intra-familial members discloses a considerable overlap between ALS and FTD.

**Causative genes**

Since the identification of first causative gene in 1993, a growing number of ALS-causing genes associated with Mendelian inheritance have been identified. Although FALS represents only 5 ~ 10 % of ALS cases, investigations of the causative genes have greatly increased our understanding of the etiology of ALS. FALS is generally inherited in an autosomal dominant pattern and rarely inherited as an autosomal recessive or X-linked trait [10]. Adult onset autosomal dominant inheritance is more common than juvenile onset which is usually caused by recessive transmission.

To date, at least 21 chromosomal regions containing 19 identified genes have been linked to ALS, termed as ALS 1~21 respectively (Table 1). In 2011, the chromosome 9 open reading frame 72 (C9ORF72) repeat expansions were identified in a significant proportion of ALS and FTD patients, becoming the most common genetic cause of ALS in the Caucasian population. There has been strong evidence to support the pathogenic role for mutations in Cu/Zn superoxide dismutase 1 (SOD1), Fused in sarcoma (FUS), TAR DNA-binding protein (TARDBP), and C9ORF72. However, mutations in other genes are not common or even rarely seen in ALS cases. In addition to the aforementioned ALS genes, a constellation of other genes have also been implicated in ALS [11]. But mutations in these genes are only identified in a small fraction of ALS patients, indicating that these mutated genes have little contribution to the development of ALS.

**Genotype-phenotype correlations**

**ALS1: SOD1**

The first causative gene of ALS was identified as **SOD1** in 1993 [12]. Mutations in **SOD1** are very common, accounting for about 20 % of FALS and 1 ~ 2 % of SALS cases [13]. To date, more than 185 disease-associated mutations have been described, spread throughout all the 5 exons of **SOD1** [14]. The majority of **SOD1** mutations are missense mutations, while small deletions or insertions are also described [15]. The pattern of inheritance is autosomal dominant except for the p.D90A mutation which is recessive in the Scandinavian population and dominant in others [16]. Among the **SOD1** mutations, p.D90A is the most common worldwide. However, regional disparity of **SOD1** mutations also exists. For example, the most frequent **SOD1** mutation in North America is p.A4V [17], but in the UK and Japan, the most common mutations are p.I113T, and p.H46R, respectively [18].

Overall, most patients with **SOD1** mutations develop a rapidly progressive ALS, although some cases show a diverse phenotype. AAO and severity may vary significantly depending on the variants involved. Patients with p.A4V, p.H43R, p.L84V, p.G85R, p.N86S, or p.G93A mutations exhibit an aggressive form of ALS with survival shorter than 3 years, while cases with p.G93C, p.D90A, or p.H46R mutations show longer life expectancies [18]. Cognitive impairment is very rare and bulbar onset is less frequent than in other FALS types [19]. Some cases with **SOD1** mutations have distinct clinical features. Patients carrying homozygous p.D90A mutation manifest insidious onset and a slow progression of ALS, with bladder involvement at the later stage [20]. In contrast, heterozygous p.D90A mutation is associated with various forms of ALS, including bulbar onset, upper-limb onset and fast progression, and lower-limb onset with fast progression [21, 22]. The p.A4V mutation causes a limb-onset aggressive form of ALS, with survival less than 2 years after the onset [23]. Cases with p.A4T mutation have a similar phenotype to that seen in p.A4V mutation [24]. We previously reported **SOD1** p.C111Y and p.G147D mutations in 3 Chinese ALS families. The p.C111Y mutation led to a relatively mild ALS phenotype, while the p.G147D was associated with a rapid progressive ALS [25]. The recently reported novel p.R115C mutation was identified in an ALS patient who had an extremely rapid progression and aggressive phenotype.
| ALS type | Gene | Inheritance | ALS features | FTD | Other features/disorders |
|----------|------|-------------|--------------|-----|-------------------------|
| ALS 1    | SOD1 | AD; AR; De novo | AAO: adult > juvenile; Onset: LL > UL > bulbar; Progression: rapid > slow; UMN + LMN > LMN dominant | Rare | PMA, PBP, BFA, cerebellar ataxia, autonomic dysfunction |
| ALS 2    | ALSIN| AR          | AAO: juvenile; Onset: LL, UL; Progression: slow; UMN dominant > UMN + LMN | None | PLS, IAHSP |
| ALS 3    | UN   | AD          | N/A          | N/A | N/A                     |
| ALS 4    | SETX | AD          | AAO: juvenile > adult; Onset: LL > UL; Progression: slow; UMN + LMN > LMN dominant | None | AOA2, cerebellar ataxia, motor neuropathy |
| ALS 5    | SPG11| AR          | AAO: juvenile > adult; Onset: bulbar, limb; Progression: N/A; UMN + LMN > UMN + LMN dominant | Rare | HSP, autonomic dysfunction, mental retardation |
| ALS 6    | FUS  | AD; AR; De novo | AAO: adult > juvenile; Onset: UL, bulbar > LL; Progression: rapid > slow; UMN + LMN > LMN dominant | Rare | PMA, Parkinsonism, essential tremor, mental retardation |
| ALS 7    | UN   | AD          | N/A          | N/A | N/A                     |
| ALS 8    | VAPB | AD          | AAO: adult > juvenile; Onset: limb; Progression: slow; UMN + LMN | None | SMA, motor neuropathy, autonomic dysfunction |
| ALS 9    | ANG  | AD          | AAO: adult > juvenile; Onset: limb, bulbar; Progression: N/A; UMN + LMN | Yes | PBP, PD |
| ALS 10   | TARDBP| AD; AR | AAO: adult; Onset: limb, bulbar; Progression: variable; UMN, LMN | Yes | PSP, FTD with Parkinsonism, PD, chorea |
| ALS 11   | FIG4 | AD          | AAO: adult; Onset: bulbar > limb; Progression: variable; UMN + LMN > UMN dominant | None | CMT4J, HSP, PLS, Yunis–Varon syndrome, epilepsy with polymicrogyria |
| ALS 12   | OPTN | AD; AR      | AAO: adult; Onset: bulbar, limb; Progression: slow; UMN + LMN | Yes | POAG, Parkinsonism, aphasia |
| ALS 13   | ATXN2| AD          | AAO: adult > juvenile; Onset: UL, LL; Progression: variable; UMN + LMN | None | SCA2, Parkinsonism |
| ALS 14   | VCP  | AD          | AAO: adult > juvenile; Onset: limb > bulbar; Progression: variable; UMN + LMN | Yes | IBMPFD |
| ALS 15   | UBQLN2| XD       | AAO: adult > juvenile; Onset: limb, bulbar; Progression: variable; UMN + LMN > UMN dominant | Yes | PLS |
| ALS 16   | SIGMAR1| AD  | AAO: juvenile; Onset: LL > UL; Progression: N/A; UMN + LMN | Rare | motor neuropathy |
| ALS 17   | CHMP2B| AD         | AAO: adult; Onset: bulbar, limb; Progression: N/A; UMN + LMN > LMN dominant | Yes | PMA; Parkinsonism |
| ALS 18   | PFN1 | AD          | AAO: adult; Onset: limb; Progression: N/A; UMN + LMN | None | N/A |
| ALS 19   | ERBB4| AD          | AAO: adult; Onset: UL, bulbar; Progression: slow; UMN + LMN | None | N/A |
| ALS 20   | hnrNPA1| AD      | AAO: adult; Onset: N/A; Progression: N/A; UMN + LMN > LMN dominant | Yes | multisystem proteinopathy |
| ALS 21   | MATR3| AD          | AAO: adult; Onset: bulbar, limb; Progression: N/A; UMN + LMN > LMN dominant | Yes | distal myopathy |
ALS2: Alsin
Mutations in ALS2 are responsible for autosomal recessive, early-onset forms of upper motor neuron diseases, such as infantile ascending hereditary spastic paraplegia (IAHSP) and juvenile primary lateral sclerosis (PLS) [28, 29]. To date, more than 50 patients with early onset (~1 year) of the disease have been reported to harbor Alsin mutations [18]. In the typical adult onset ALS, Alsin gene is rarely mutated [30]. Recently, a novel splice-site mutation (c.3512 + 1G > A) in Alsin was identified in a consanguineous JALS family with early onset anarthria and generalized dystonia [31].

ALS4: senataxin (SETX)
ALS4 is a rare autosomal dominant form of juvenile-onset ALS due to mutations in SETX [32]. It is characterized by slowly evolving distal muscle weakness and atrophy, pyramidal signs, and sparing of bulbar and respiratory muscles [33]. In some cases, normal lifespan or atypical features are also described [34, 35]. A patient with SETX p.R2136C mutation presented with coexistence of ALS and inflammatory radiculoneuropathy [36]. We previously reported a missense mutation p.T1118I in a sporadic Chinese ALS patient who developed bulbar symptoms 3 years after the onset, and respiratory failure 2 years later [37]. In addition, recessive SETX mutations are reported to cause ataxia and oculomotor apraxia type 2 (AOA2) [38, 39].

ALS5: spatacsin (SPG11)
SPG11 mutations were recently identified in several juvenile-onset ALS cases, with autosomal recessive inheritance and AAO ranging from 7 to 23 years [18, 40]. Generally, the SPG11-associated ALS showed a slow progression and in some cases apparent UMN involvement [41]. In addition to ALS phenotype, mutations in SPG11 also cause hereditary spastic paraplegia (HSP) with thin corpus callosum [42].

ALS6: FUS
Mutations in FUS gene have emerged as the second most common cause of ALS, accounting for about 3 ~ 5 % FALS and ~1 % SALS [43, 44]. Up to now, more than 60 mutations in FUS have been identified in ALS cases (http://www.hgmd.org, accessed in March, 2015). Among these mutations, the majority are clustered in exon 15 which encode the C-terminus of the protein, and the most common one is p.R521C [15]. The inheritance is autosomal dominant aside from an autosomal recessive p.H517Q mutation and several de novo mutations [44].

The phenotypes associated with FUS mutations include adult-onset ALS, JALS, ALS-FTD, and rarely pure FTD [45]. Although most patients carrying FUS mutations exhibit a classical ALS phenotype without cognitive impairment, the clinical course of these ALS cases are diverse, even among carriers of the same mutations. Compared to SOD1 patients, FUS-related ALS have an earlier AAO, more frequent bulbar disease, and a more rapid progression [46]. Some FUS mutations are also observed in patients with juvenile-onset ALS with AAO younger than 25 years [47, 48]. Atypical features such as ALS with mental retardation, ALS with parkinsonism and dementia [46], and essential tremor were seen in patients with FUS mutations [49].

ALS8: vesicle associated membrane protein B (VAPB)
VAPB mutation was firstly described in several Brazilian families with motor neuron degeneration of various patterns: late-onset spinal muscular atrophy, atypical ALS, or typical ALS [50]. Subsequently, five other point mutations and a small deletion were described. Overall, VAPB mutations are extremely rare in FALS. The phenotype-genotype correlation remains largely undetermined so far.

ALS9: angiogenin (ANG)
The role of ANG mutations in ALS remains ambiguous. Approximately 30 ANG mutations have been reported in ALS, but only the p.K17II mutation is shown to cosegregate with the disease [51]. Mutations in ANG account for a small fraction of ALS cases. A few FALS cases are identified to have concomitant ANG mutations
with FUS [52] or SOD1 [53] mutations. In addition, some ANG mutations are detected in healthy controls [54]. A subset of ANG mutation carriers showed cognitive impairment suggestive of FTD [55], or Parkinson’s disease (PD) [56].

**ALS10: TARDBP**

Mutations in TARDBP encoding TDP-43 account for 4% of FALS cases and ~1% of SALS [57, 58]. More than 50 mutations have been identified so far (http://www.hgmd.org, accessed in March, 2015), mostly clustered in the C-terminal region encoded by exon 6 of TARDBP. Mutations in TARDBP are predominantly missense with an autosomal dominant inheritance. Although TARDBP mutations are detected in ALS cases worldwide, some regional diversity does exist. For instance, the p.A382T mutation has been found in 28.7% of all ALS cases in Sardinia [59].

Patients with TARDBP mutations usually exhibit a typical ALS phenotype, with limb or bulbar onset, variable disease course, and no overt dementia [60]. It is reported that the TARDBP–linked ALS has a trend for earlier AAO, more upper limb onset, and a longer duration, compared to SALS patients [52, 61]. However, we previously reported a TARDBP p.S292N mutation in a FALS case who developed dysarthria, dysphagia, and atrophy of lingual muscle at the age of 64 years [62]. The progression of ALS in this case seemed to be rapid. Other phenotypes associated with TARDBP mutations include FTD [63], ALS–FTD [64], ALS with extrapyramidal signs [65], FTD with parkinsonism [66], and PD [67].

**ALS11: factor induced gene 4 (FIG4)**

FIG4 was previously implicated in Charcot-Marie-Tooth disease type 4J (CMT4J) [68]. Later, FIG4 mutations were found in autosomal dominant FALS and SALS cases [69]. However, ALS was a rare phenotype of FIG4 gene. The other phenotypes associated with FIG4 mutations include PLS [69], Yunis–Varon syndrome [70], and familial epilepsy with polymicrogyria [71].

**ALS12: optineurin (OPTN)**

Previously identified as the cause of primary open angle glaucoma (POAG) [72], mutations in OPTN have been found in both FALS and SALS cases in either a dominant or recessive manner [73]. Although OPTN mutations are relatively common in Japan ALS cases [73, 74], they are rare in Caucasian patients [75, 76]. The OPTN-related ALS showed relatively slow progression and long duration before respiratory dysfunction [73]. In addition to ALS phenotype, some patients with OPTN mutations present with extrapyramidal symptoms, aphasia, or FTD [77, 78].

**ALS13: Ataxin-2 (ATXN2)**

Long (more than 33) CAG repeat expansion in ATXN2 gene has been identified as a cause of spinocerebellar ataxia type 2 (SCA2) [79]. Recent studies demonstrated that intermediate expansion (27–33 repeats) of ATXN2 was a significant risk factor for ALS [80–82]. However, whether the clinical features of ALS can be affected by ATXN2 intermediate repeats is still controversial, because no correlation between ATXN2 repeat length and AAO or survival was observed [83]. A few case reports have described motor neuron degeneration in SCA2 families, raising the possibility that motor neuron involvement is part of SCA2 [84, 85].

**ALS14: Valosin-containing protein (VCP)**

The gene of VCP is known to be mutated in inclusion body myopathy with Paget disease of bone and frontotemporal dementia (IBMPFD) [86]. Recently, mutations in VCP were identified in patients with FALS or SALS [87]. Actually, VCP mutations are not a major cause of ALS. Although more than 38 mutations in VCP have been discovered (http://www.hgmd.org, accessed in March, 2015), only a few of them are responsible for ALS. The phenotype of patients with VCP mutations shows intra-familial variations from IBMPFD to FALS [88], or from ALS to FTD or ALS–FTD [87].

**ALS15: ubiquilin 2 (UBQLN2)**

Mutations in UBQLN2 were recently identified in X-linked dominant FALS [89]. However, UBQLN2 mutations are not a frequent cause of ALS [90]. In the affected cases, incomplete penetrance has been noted in females [89]. The predominant phenotype associated with UBQLN2 mutations is ALS, although several patients have concomitant symptoms of FTD [10]. The AAO has been reported to be significantly younger in males than in females, presumably because males are hemizygous but females are heterozygous for the mutation [89].

**ALS16: sigma non-opioid intracellular receptor 1 (SIGMAR1)**

SIGMAR1 mutations were recently identified in families affected with juvenile ALS [91] or ALS with dementia [92]. However, these findings have not been replicated by other groups, suggesting that SIGMAR1 is a rare causative gene of ALS. Recently a splice-site mutation (c.151 + 1G > T) in SIGMAR1 was reported to cause autosomal recessive distal hereditary motor neuropathy in a consanguineous Chinese family [93].

**ALS17: chromatin modifying protein 2B (CHMP2B)**

Mutations in the CHMP2B gene were initially identified in patients with FTD [94] and then identified in
patients with ALS [95, 96]. Since only several ALS cases with CHMP2B mutations were reported, there was no characteristic ALS clinical subtype associated with these patients. In addition, CHMP2B mutation (p.R69Q) was also identified in progressive muscular atrophy (PMA) [96].

ALS18: profilin 1 (PFN1)
Missense mutations inPFN1 are firstly reported in two large ALS families and 7 FALS patients [97]. Later, screenings of sizeable ALS and FTD cohorts from diverse populations demonstrated that PFN1 mutations are a rare cause of ALS [98–100]. The reported cases with PFN1 mutations seem to present classical ALS with limb onset and no evidence of FTD [97, 99, 101].

ALS19: erb-b2 receptor tyrosine kinase 4 (ERBB4)
Recently, ERBB4 was identified a causative gene of FALS19, which was characterized by typical, slowly progressive ALS and a lack of obvious cognitive dysfunction [102]. However, this finding has not been replicated by other groups. The genotype-phenotype correlations are thus not determined.

ALS20: heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)
Mutations inhnRNPA1 gene were recently identified in patients presenting with ALS and/or multisystem proteinopathy (MSP) [103]. However, subsequent studies failed to identifyhnRNPA1 mutations in patients with ALS, FTD, or MSP [103–105]. The associations of ALS withhnRNPA1 mutations are still controversial.

ALS21: matrin-3 (MATR3)
Several mutations inMATR3 were recently reported to cause ALS [106]. Later, a heterozygousMATR3 p.A72T mutation was identified in a sporadic ALS patient with bulbar onset [107]. In another study, 2 splicing variants and a missense mutation were identified in 3 ALS cases with AAO ranging from 58 to 79 years, and bulbar onset in 2 cases [108].

ALS-FTD: C9ORF72
In 2011, two independent groups reported that the massive GGGGCC hexanucleotide repeat expansion in the non-coding regions of C9ORF72 gene caused chromosome 9p-linked ALS and FTD [109, 110]. Currently, C9ORF72 repeat expansions have become the most frequently genetic cause of FALS and familial FTD, accounting for about 40 and 25 % of the cases, respectively [13]. In families with ALS-FTD, the frequency reaches to 50–72 % [19]. Notwithstanding, the mutations seem to be geographically clustered, accounting for one third of FALS cases in Europe and North America, but a small percentage in Asian populations. Haplotype analysis indicates that a common European founder appears to be responsible for all cases [111].

The C9ORF72 repeat expansions are associated with various phenotypes, including typical ALS, PMA, PLS, ALS-FTD, and pure FTD [44]. In patients with C9ORF72 mutations, bulbar onset and cognitive impairment seems to be more frequent, and median survival is relatively lower than in patients carrying TARDBP or SOD1 mutations [19]. However, there is no association between the repeat length and disease phenotype or AAO in C9ORF72 mutation carriers [112]. In addition, the C9ORF72 expansions also underlie a small portion of other neurological diseases, such as Alzheimer’s disease (AD) [113], Huntington’s disease (HD) [114], and PD [115].

Other genes implicated in ALS
Several other genes are also implicated in ALS. DCTN1 mutations were first identified in a family affected with LMN disease [116] and soon identified in several ALS families [117, 118]. Subsequently, a cluster of DCTN1 mutations were identified in pedigrees with Perry syndrome [119], PD [120] or progressive supranuclear paralysis (PSP) [121], suggestive of phenotypic variability of DCTN1 mutations. Mutations in SQSTM1 were initially identified as a cause of Paget disease of bone (PDB) [122]. Recently, SQSTM1 mutations were identified in ALS [123, 124] as well as FTD [125]. It is speculated that SQSTM1 mutations are mainly associated with late-onset SALS, because the number of early-onset patients with SQSTM1 mutations is much less than that of late-onset patients with SQSTM1 mutations [126].

In addition, mutations in several other genes such as DAO, UNCI3A, NEFH, PRPH, TAF15, and ELP3, have been reported as rare causes of ALS. For some genes, there are no additional reports about the mutations as a cause of ALS since the initial publications. Therefore, the evidence supporting a causative role of ALS is not fully convincing.

Implication of the genotype-phenotype correlations
There is no a standard procedure to test the causative mutation in cases with ALS. Many factors should be considered, such as AAO, clinical features, progression, FTD involvement, inheritance manner, and even ethnicity. In this review, we summarized the possible genotype-phenotype correlations of ALS with the aim of providing some clue to improve the clinical decision. Here, we provided a flow diagram of genetic screening strategy in cases diagnosed with ALS (Fig. 1). AAO is an importance factor for the genetic investigations and can be divided into juvenile onset and adult onset. Juvenile
Fig. 1 A flow diagram of genetic screening strategy in cases diagnosed with ALS

onset is usually present in ALS1, ALS2, ALS4, ALS5, ALS6, ALS8, ALS9, ALS13, ALS15, and ALS16. For these cases with juvenile onset and UMN dominant symptoms, Alsin, SPG11, SIGMAR1, or UBQLN2 might be a causative gene. In contrast, FUS, VAPB, SOD1, and SETX should be considered in cases with juvenile onset and LMN dominant phenotype. For these cases with juvenile onset and FTD symptoms, ANG, UBQLN2, and SIGMAR1 can be investigated. In addition, SPG11 and FUS can be sequenced in cases who also present mental retardation, while SOD1, Alsin, SETX, ATXN2 can be considered in those cases with coexistence of cerebellar ataxia.

In cases with adult-onset ALS, many genes should be considered. Although the majority exhibit typical ALS features with both UMN and LMN symptoms, a fraction of cases present either UMN dominant symptoms or LMN dominant symptoms. SPG11, FIG4, UBQLN2 may be mutated in cases with UMN dominant symptoms. In these cases with LMN dominant symptoms, mutations in SOD1, SETX, FUS, VAPB, VCP, CHMMP2B, hnRNP1, or MATR3 might be identified. Presence of FTD hints possible mutations in ANG, TARDBP, OPTN, VCP, UBQLN2, CHMMP2B, hnRNP1, MATR3, or C9ORF72. Motor neuropathy involvement might occur in cases with mutations in SETX, VAPB, or FIG4. Complications of ataxia may be seen in cases with SOD1 or ATXN2 mutations.

Inheritance pattern also provides critical information as to the potential involvement of one or other specific genes in ALS. However, the diverse clinical features between intra-familial cases or a deceased parent at a young age may result in the appearance of “lack of familial history” in some cases. The presentation of ALS or FTD in first-degree relatives and the co-occurrence of ALS with FTD in some patients with ALS supported a positive family history. In addition, ethnic background should be considered when determining which genes are most likely. For example, C9ORF72 has been regarded as the most common cause of ALS in Caucasians, but very rare in Asian population.

Conclusions

Here, we outline the genotype-phenotype correlations of ALS. We hope this review is helpful for detecting the causative mutation in cases with ALS. Although a number of genes have been reported, many ALS cases still do not carry any mutation in the aforementioned genes. Other more genes might be identified as causative genes of ALS in the future.

Abbreviations

AAO: age at onset; AD: Alzheimer’s disease; ALS: amyotrophic lateral sclerosis; ANG: angiogenin; AOA2: oculomotor apraxia type 2; ATXN2: ataxin-2; C9ORF72: chromosome 9 open reading frame 2; CMT4J: Charcot-Marie- Tooth disease; DCTN1: dynactin; DRB4: erb-b2 receptor tyrosine kinase 4; FALS: familial amyotrophic lateral sclerosis; FIG4: factor induced gene 4; FTD: frontal temporal dementia; FUS: fused in sarcoma; HD: Huntington’s disease; hnRNP1: heterogeneous nuclear ribonucleoprotein A1; HSP: hereditary spastic paraplegia; IAHSP: infantile-onset ascending hereditary spastic paraplegic; IBMPFD: inclusion body myopathy with Paget disease of bone and frontotemporal dementia; JALS: juvenile amyotrophic lateral sclerosis; LMN: lower motor neuron; MATR3: matrin-3; MSP: multisystem proteinopathy; OPTN: optineurin; PDB: Paget disease of bone; PLS: juvenile primary lateral sclerosis; PMA: progressive muscular atrophy; PSP: progressive supranuclear paralysis; SALS: sporadic amyotrophic lateral sclerosis; SCA: spinocerebellar ataxia; SETX: senataxin; SIGMAR1: sigma non-oxipid intracellular receptor 1; SOD1: superoxide dismutase 1; SPG11: spastin; SQSTM1: sequestosome 1; TARDBP: TAR DNA-binding protein; UBQLN2: ubiquilin 2; UMN: upper motor neuron; VAPB: vesicle associated membrane protein B.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

L-HF drafted and W-ZY critically revised the manuscript. Both authors read and approved the final manuscript.

Acknowledgements

This work was supported by grants from the National Natural Science Foundation to Zhi-Ying Wu (81125009, Beijing).

Received: 1 July 2015 Accepted: 27 January 2016

Published online: 03 February 2016

References

1. Logroscino G, Traynor BJ, Hardiman O, Chio A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81:385–90.
2. Sithasivam S. Motor neurone disease: clinical features, diagnosis, diagnostic pitfalls and prognostic markers. Singapore Med J. 2010;51:367–72. quiz 73.
3. Finsterer J, Burgunder JM. Recent progress in the genetics of motor neuron disease. Eur J Med Genet. 2014;57:103–12.
4. Forbes RB, Colville S, Swingler RJ. The epidemiology of amyotrophic lateral sclerosis (ALS/MND) in people aged 80 or over. Age Ageing. 2004;33:131–4.
5. Gouveia LO, de Carvalho M. Young-onset sporadic amyotrophic lateral sclerosis: a distinct nosological entity? Amyotroph Lateral Scler. 2007;8:323–7.
6. McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gend Med. 2010;7:557–70.
7. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942–55.
8. Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65:586–90.
9. Burrell JR, Kiernan MC, Vucic S, Hodges JR. Motor neuron dysfunction in frontotemporal dementia. Brain. 2011;134:2582–94.
10. Ferrante AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17:17–23.
11. Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neuro. 2013;9:517–28.
12. DengHX, Hentati A, Tainer JA, Ishal Z, Cayabyab A, Hung WY, et al. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science. 1993;261:1047–51.
13. Baumer D, Talbot K, Tumer MR. Advances in motor neurone disease. J R Soc Med. 2014;107:14–21.
14. Tortelli R, Conforti FL, Cortese R, D’Enrico E, Distaso E, Mazzei R, et al. Amyotrophic lateral sclerosis: a new missense mutation in the SOD1 gene. Neurobiol Aging. 2013;17:909(34)e3–5.
15. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nature reviews. Neurology. 2011;7:605–15.
16. Jonsson PA, Backstrand A, Andersen PM, Jacobsson I, Parton M, Shaw C, et al. Cu/Zn-superoxide dismutase in D90A heterozygotes from recessive and dominant affected SOD1 ALS pedigrees. Neurobiol Dis. 2002;10:3273–30.
17. Sacerd M, Yang Y, Deng HX, Hung WY, Siddique N, Delleflae L, et al. Age and dominant effect of SOD1 A4V mutation causing ALS. Neurology. 2009;72:1634–9.
18. Yamashita S, Ando Y. Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis. Arch Neurol. 2003;60:1768.
19. Visani M, de Biase D, Bartolomei I, Plasmati R, Morandi L, Cenacchi G, et al. A novel T137A SOD1 mutation in an Italian family with two subjects affected by amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12:233–7.
20. Ikuchi Y, Katsuno M, Ikenaka K, Ishigaki S, Sobue G. Amyotrophic lateral sclerosis: an update on recent genetic insights. J Neurol. 2013;260:2917–27.
21. Orlacchio A, Babalini C, Borrelli A, Patrono C, Massa R, Basaran S, et al. SPATACSN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain. 2010;133:591–8.
22. Polymendou M, Lagier-Tourenne C, Hutt KR, Bennett CF, Cleveland DW. ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology. 2010;75:584–9.
23. Polymendou M, Lagier-Tourenne C, Hutt KR, Bennett CF, Cleveland DW. ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology. 2010;75:584–9.
24. Polymendou M, Lagier-Tourenne C, Hutt KR, Bennett CF, Cleveland DW. ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology. 2010;75:584–9.
25. Polymendou M, Lagier-Tourenne C, Hutt KR, Bennett CF, Cleveland DW. ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology. 2010;75:584–9.
26. Bojan K. Familial Amyotrophic Lateral Sclerosis. Neurol Clin. 2015;33:807–30.
27. DoriO, Basso P, Torelli A, Zanuttini D, Friel E, Panzini M, et al. Novel A51T TARDBP mutation in a family with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2014;85:1359–62.
28. Boylan K. Familial Amyotrophic Lateral Sclerosis. Neurol Clin. 2015;33:807–30.
29. Deng H, Gao K, Jankovic J. The role of FUS gene variants in neurodegenerative diseases. Nat Rev Neuro. 2014;10:337–48.
30. Jan Y, Deng HX, Siddique N, Fecto F, Chen W, Yang Y, et al. Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/ dementia. Neurology. 2010;75:807–14.
31. Baumer D, Hilton D, Painie SM, Turner MR, Lowe J, Talbot K, et al. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology. 2010;75:611–8.
32. Munoz DG. FUS mutations in sporadic juvenile ALS: another step toward understanding ALS pathogenesis. Neurology. 2010;75:5584–5.
33. Nishimura AL, Mitne-Neto M, Silva HC, Richieri-Costa A, Middleton S, Cascio D, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet. 2006;79:822–31.
34. van Es MA, Diekstra FP, Veldink JH, Baas F, Bourque PR, Schelhaas HJ, et al. Accumulation of TDP-43 and alpha-actin in an amyotrophic lateral sclerosis patient with the K17I ANG mutation. Acta Neuropathol. 2014;127:421–34.
35. Chen YZ, Bennett CL, Huynh HM, Blair IP, Puls I, Irobi J, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet. 2004;74:1128–35.
36. Hirano M, Quirzi CM, Mitsuimoto H, Hays AP, Roberts JK, Richard P, et al. Senataxin mutations and amyotrophic lateral sclerosis. Amyotrophic Lateral Scler. 2011;12:233–7.
37. Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci. 2006;7:710–23.
38. Rabin BA, Griffin JW, C lain BJ, Scavina M, Chance PF, Comblath DR. Autosomal dominant juvenile amyotrophic lateral sclerosis. Brain. 1999;122( Pt 8):1539–50.
39. Saiga T, Tateishi T, Tani T, Kawamura N, Nagara Y, Shigeto H, et al. Inflammatory radioculoneuropathy in an ALS4 patient with a novel SETX mutation. J Neurol Neurosurg Psychiatry. 2012;83:763–4.
40. Zhao ZH, Chen WZ, Wu ZY, Wang N, Zhao GX, Chen WJ, et al. A novel mutation in the senataxin gene identified in a Chinese patient with sporadic amyotrophic lateral sclerosis. Amyotrophic Lateral Scler. 2009;10:118–22.
41. Chen YZ, Hashemi SH, Anderson SK, Huang Y, Moreira MC, Lynch DR, et al. Senataxin, the yeast Sen1p orthologue: characterization of a unique protein in which recessive mutations cause ataxia and dominant mutations cause motor neuron disease. Neurobiol Dis. 2006;23:397–108.
42. Moreira MC, Klu S, Watanabe M, Nemeth AH, Le Ber I, Moniz XC, et al. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-oculomotor apraxia 2. Nat Genet. 2004;36:225–7.
43. Orlacchio A, Babalini C, Borrelli A, Patrono C, Massa R, Basaran S, et al. SPATACSN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain. 2010;133:591–8.
44. Boylan K. Familial Amyotrophic Lateral Sclerosis. Neurol Clin. 2015;33:807–30.
45. Deng H, Gao K, Jankovic J. The role of FUS gene variants in neurodegenerative diseases. Nat Rev Neuro. 2014;10:337–48.
46. Jan Y, Deng HX, Siddique N, Fecto F, Chen W, Yang Y, et al. Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/ dementia. Neurology. 2010;75:807–14.
47. Baumer D, Hilton D, Painie SM, Turner MR, Lowe J, Talbot K, et al. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology. 2010;75:611–8.
48. Munoz DG. FUS mutations in sporadic juvenile ALS: another step toward understanding ALS pathogenesis. Neurology. 2010;75:5584–5.
49. Nishimura AL, Mitne-Neto M, Silva HC, Richieri-Costa A, Middleton S, Cascio D, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet. 2006;79:822–31.
50. van Es MA, Diekstra FP, Veldink JH, Baas F, Bourque PR, Schelhaas HJ, et al. A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation. Neurology. 2009;72:287–8.
102. Takahashi Y, Fukuda Y, Yoshimura J, Toyoda A, Kurppa K, Morito Y, et al. ERBB4 mutations that disrupt the neuregulin-ERbb4 pathway cause amyotrophic lateral sclerosis type 1. Am J Hum Genet. 2013;93:900–5.

103. Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diao Z, et al. Mutations in prion-like domains in hnRNP A2/B1 and hnRNP A1 cause multisystem proteinopathy and ALS. Nature. 2013;496:467–73.

104. Seelen M, Visser AE, Overste Dj, Kim HJ, Palud A, Wong TH, et al. No mutations in hnRNPA1 and hnRNPA2B1 in Dutch patients with amyotrophic lateral sclerosis, frontotemporal dementia, and inclusion body myopathy. Neurobiol Aging. 2014;35:934. e5–6.

105. Le Ber I, Van Bertel J, Nicolas G, Bouya-Ahmed K, Camuzat A, Wallon D, et al. hnRNPA2B1 and hnRNP A1 mutations are rare in patients with “multisystem proteinopathy” and frontotemporal lobar degeneration phenotypes. Neurobiol Aging. 2014;35:934. e5–6.

106. Johnson JO, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE, et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci. 2014;17:664–6.

107. Lin KP, Tsai PC, Liao YC, Chen WT, Tsai CP, Soong BW, et al. Mutational analysis of MATR3 in Taiwanese patients with amyotrophic lateral sclerosis. Neurobiol Aging. 2005;26:36(e1–4).

108. Leblond CS, Gan-Or Z, Spiegelman D, Laurent SB, Szuto A, Hodgkinson A, et al. Replication study of MATR3 in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2015;37:209.

109. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245–56.

110. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257–68.

111. Smith BH, Newhouse S, Shatunov A, Vance C, Topp S, Johnson L, et al. The C9orf72 expansion mutation is a common cause of ALS+/−FTD in Europe and has a single founder. Eur J Hum Genet. 2013;21:1002–8.

112. Rutherford NJ, Heckman MG, DeJesus-Hernandez M, Baker MC, Soto-Ortolaza AL, Rayaprolu S, et al. Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiol Aging. 2012;33:2950. e5–7.

113. Majounie E, Abramzon Y, Renton AE, Perry R, Bassett SS, Pletnikova O, et al. DCTN1 mutation analysis in families with progressive supranuclear palsy-like phenotypes. Neurology. 2014;82:292–9.

114. Hirano M, Nakamura Y, Saigoh K, Sakamoto H, Ueno S, Isono C, et al. Mutations in the gene encoding p62 in Japanese patients with amyotrophic lateral sclerosis. Neurology. 2013;80:458–63.

115. Rubino E, Rainero I, Chio A, Rogaeva E, Galimberti D, Fenoglio P, et al. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology. 2012;79:1556–62.

116. Chen Y, Zheng ZZ, Chen X, Huang R, Yang Y, Yuan L, et al. SQSTM1 mutations in Han Chinese populations with sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2014;35:726. e7-9.